<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820651</url>
  </required_header>
  <id_info>
    <org_study_id>DIAMEL_NASH-09</org_study_id>
    <nct_id>NCT00820651</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether the addition of Diamel, a nutritional
      supplement, to hypocaloric diet and exercise could improve the histological results
      (steatosis, necro-inflammatory activity and fibrosis), insulin resistance, aminotransferase
      levels and anthropometric measures in comparison with a placebo-controlled group with
      hypocaloric diet and exercise during 52 weeks of treatment in patients with nonalcoholic
      steatohepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The histological improvement (steatosis, necro-inflammatory activity and fibrosis) at 52 weeks (end of the treatment) as compared with pre-treatment liver biopsy.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulinresistance levels (HOMA-IR) at 52 weeks (end of the treatment), Aminotransferase levels at 52 weeks (end of the treatment), Body weight, Body Mass Index and waist circumference at 52 weeks (end of the treatment)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diamel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diamel</intervention_name>
    <description>Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks</description>
    <arm_group_label>Diamel</arm_group_label>
    <other_name>Dietary supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo and lifestyle counseling</intervention_name>
    <description>Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with &lt;10% of saturated fatty acids and protein 14%, and exercise)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Lifestyle modification</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of steatohepatitis (minimal histological criteria for
             steatohepatitis include steatosis involving at least 5% of hepatocytes, lobular
             inflammation, and/or fibrosis)

          -  Age between 18 and 70 years

          -  Ability to provide informed consent

          -  Absence of significant alcohol ingestion (weekly ethanol consumption of less than 40
             g)

        Exclusion Criteria:

          -  Presence of other form of liver diseases (viral or autoimmune hepatitis, drug-induced
             liver disease, metabolic and hereditary liver disease and α-1 antitrypsin deficiency)

          -  Pregnancy or lactation

          -  Decompensated cirrhosis

          -  Presence of secondary cause of NAFL such as medications that induce steatosis
             (corticosteroids, estrogens, methotrexate, amiodarone, tamoxifen and calcium channel
             blockers) and gastrointestinal bypass surgery

          -  Pharmacological treatment with some potential benefit on NAFL including
             ursodeoxycholic acid, vitamin E, betaine, pioglitazone, rosiglitazone, metformin,
             pentoxifylline or gemfibrozil

          -  Fasting glucose levels greater than 250 mg per deciliter (13.3 mmolm per liter)

          -  Contraindication to liver biopsy

          -  Refusal to participate in the study

          -  Concomitant disease with reduced life expectancy

          -  Severe psychiatric conditions

          -  Drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Vilar Gomez, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Gastroenterology</name>
      <address>
        <city>Vedado</city>
        <state>Havana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <link>
    <url>http://www.sediabetes.org/resources/revista/00011246archivoarticulo.pdf</url>
    <description>Paper published in full text version</description>
  </link>
  <results_reference>
    <citation>Hernandez Yero JA, Vargas Gonzalez D. Utilidad de Diamel en pacientes con diabetes mellitus tipo 2 en tratamiento combinado con glibenclamida. Avances en Diabetología 23(1):284-290, 2007</citation>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>Insulinresistance</keyword>
  <keyword>Diet and exercise</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Lifestyle modifications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

